October 22, 2014 4:59 AM ET


Company Overview of Point Therapeutics Inc

Company Overview

As of February 12, 2008, Point Therapeutics Inc. was acquired by Dara BioSciences Inc., in a reverse merger transaction. Point Therapeutics, Inc., a development stage biopharmaceutical company, engages in the development of dipeptidyl peptidase (DPP) inhibitors for use in cancer and type 2 diabetes. Its DPP inhibitors are enzymes that regulate various physiological processes involved in tumor growth and host responses to cancer and type 2 diabetes. The company’s lead product candidate, talabostat is in Phase III a clinical trial for the treatment of metastatic nonsmall cell lung cancer. Point Therapeutics also develops PT-630, a DPP inhibitor and preclinical lead drug candidate, which is use...

70 Walnut Street

Wellesley Hills, MA 02481

United States

Founded in 1993





Key Executives for Point Therapeutics Inc

Point Therapeutics Inc does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Agradis, Inc. United States
HB Custom Media, Inc. United States
Plough Boy Organics, LLC United States
ArmaGen Technologies, Inc. United States
Genovo, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Point Therapeutics Inc, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.